Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
DA-EPOCH is a dose-adjusted chemotherapy regimen comprising etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. Developed by the National Cancer Institute (NCI), it is designed for the treatment of aggressive lymphomas, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and T-cell lymphomas. The regimen is characterized by a pharmacodynamic dose-adjustment strategy where the doses of etoposide, doxorubicin, and cyclophosphamide are titrated in subsequent cycles based on the absolute neutrophil count (ANC) nadir of the previous cycle. This approach aims to optimize dose intensity for individual patients while minimizing severe hematologic toxicity. It is often administered as a 96-hour continuous intravenous infusion.
- Other names
- Dose-Adjusted EPOCHEPOCH
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin.